Catalyst Biosciences Reports Second Quarter 2017 Financial Results And Provides Subcutaneous (SQ) Hemophilia Program Update

Published: Aug 03, 2017

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced financial results for the second quarter ended June 30, 2017 and provided a corporate update.

Recent Milestones: Factor IX SQ CB 2679d (also known as ISU304)

Initiated and completed dosing of first patient cohort in Phase 1/2 clinical trial of subcutaneous (SQ) CB 2679d in individuals with hemophilia B;

Back to news